Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations
- 23 October 2018
- journal article
- review article
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 13 (6) , 588-595
Abstract
Purpose of Review Although BCR-ABL1-negative myeloproliferative neoplasms (MPN) are chronic, clonal hematopoietic stem cell (HSC) disorders marked by proliferation of one or more myeloid lineages, a substantial proportion of patients transform to acute myeloid leukemia. Leukemic transformation (LT) from a pre-existing MPN carries a dismal prognosis. Here, we review recent genetic, biological, and clinical data regarding LT. Recent Findings In the last decade, DNA sequencing has revolutionized our understanding of the genomic landscape of LT. Mutations in TP53, ASXL1, EZH2, IDH1/2, and SRSF2 are significantly associated with increased risk of LT of MPNs. Preclinical modeling of these mutations is underway and has yielded important biological insights, some of which have therapeutic implications. Summary Recent progress has led to the identification of recurrent genomic alterations in patients with LT. This has allowed mechanistic and therapeutic insight into the process of LT. In turn, this may lead to more mechanism-based therapeutic strategies that may improve patient outcomes.Keywords
This publication has 58 references indexed in Scilit:
- Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F Without Compromising Progenitor Cell ExpansionPLOS Biology, 2013
- Mutations and prognosis in primary myelofibrosisLeukemia, 2013
- Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcomeBlood, 2012
- IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617FLeukemia, 2011
- Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative NeoplasmsJournal of Clinical Oncology, 2011
- Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3Haematologica, 2010
- JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemiaBlood, 2010
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to LeukemiasCancer Research, 2010
- The natural history and treatment outcome of blast phase BCR-ABL− myeloproliferative neoplasmsBlood, 2008